Detail
| LncRNA Name | PCSEAT |
| Synonyms | NA |
| Region | NA Sequence |
| Ensembl | NA |
| RefSeq | NA |
| Circulating | ✘ |
| Drug-resisitant | ✘ |
| Prognostic | ✘ |
| MiRNA | ✔ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR, Western blot etc. |
| Sample | cell lines (293T, PC3, DU145, LNCaP, 22Rv1, RWPE-1, 769-P, 786-O, ACHN, Calu-1 and NCI-H1299) |
| Expression Pattern | up-regulated |
| Function Description | Here, we characterized an lncRNA, PCa specific expression and EZH2-associated transcript (PCSEAT, annotated as PRCAT38), which is specifically overexpressed in PCa. Mechanistically, we found that PCSEAT promotes cell proliferation, at least in part by affecting miR-143-3p- and miR-24-2-5p-mediated regulation of EZH2, suggesting that PCSEAT and EZH2 competitively 'sponge' miR-143-3p and miR-24-2-5p. |
| Pubmed ID | 29803673 |
| Year | 2018 |
| Title | The long non-coding RNA PCSEAT exhibits an oncogenic property in prostate cancer and functions as a competing endogenous RNA that associates with EZH2 |
| External Links |
| Links for PCSEAT | GenBank HGNC lncrnadb Noncode |
| Links for prostate cancer | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.